Taxanes use and neurotoxicity in cancer patients-Reference-Cited by-同舟云学术

Taxanes use and neurotoxicity in cancer patients

Published:2021-02-18 Issue:2 Volume: Page:107-116
ISSN:2074-6822
Container-title:Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
language:ru
Short-container-title:

Author:

Tkachenko E. V.¹^ORCID,Andreev V. V.²^ORCID,Yatsenko A. V.³^ORCID,Zheltukhin A. A.⁴^ORCID,Gorbunova K. V.¹^ORCID,Kondratiev S. V.¹^ORCID,Klyuge V. A.¹^ORCID,Brish N. A.¹^ORCID,Alekseeva Yu. V.¹^ORCID,Sluzhev M. I.⁵^ORCID,Kasparov B. S.⁶^ORCID,Bondarev N. E.¹^ORCID,Mimonov E. A.¹,Semiglazov V. V.⁷^ORCID,Semiglazova T. Yu.⁸^ORCID,Belyaev A. M.⁹^ORCID

Affiliation:

1. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation

2. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation, FSBEI HE Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation

3. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation; St. Petersburg SBHI Clinical Diagnostic Center

4. SBHI St. Petersburg Clinical Scientifi c and Practical Center of Specialized Types of Medical Care (Oncology)

5. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation; FSBEI HE Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation

6. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation,

7. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation,; FSBEI HE Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation,

8. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation, St. Petersburg; FSBEI HE NorthWestern State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation, 47 Piskarevsky lane, St. Petersburg

9. FSBI N.N. Petrov NMRC of Oncology of the Ministry of Health of the Russian Federation; FSBEI HE North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation

Abstract

The review presents the data on the specifics of mechanism of action, classification, and clinical manifestations of neurotoxicity effect. The most significant features of specific side effects when using taxanes in different treatment regimens, including cumulative doses, are considered. The proven methods of treatment and prevention of neuropathy caused by anticancer drugs are discussed.

Publisher

PANORAMA Publishing House

Reference54 articles.

1. N.P. Staff, A. Grisold, W. Grisold., and A.J. Windebank. Chemotherapy-induced peripheral neuropathy: A current review. Ann. Neurol., vol. 81, no. 6, pp. 772–781, Jun. 2017, doi: 10.1002/ana.24951.

2. M. Ewertz, C. Qvortrup, and L. Eckhoff. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol, vol. 54, no. 5, pp. 587–591, May 2015, doi: 10.3109/0284186X.2014.995775.

3. J. Zhong et al. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. Thorac Cancer, vol. 10, no. 11, pp. 2088–2095, Nov. 2019, doi: 10.1111/1759-7714.13184.

4. B.A. Weaver. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell, vol. 25, no. 18, pp. 2677–2681, Sep. 2014, doi: 10.1091/mbc.E14-04-0916.

5. M.A. Jordan and L. Wilson. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, vol. 4, no. 4, pp. 253–265, Apr. 2004, doi: 10.1038/nrc1317.